AACR to honor Pfizer, Albert Bourla, PhD, for service to cancer science and medicine
Click Here to Manage Email Alerts
Pfizer Inc. and its chairman/CEO, Albert Bourla, PhD, will be awarded the 2024 AACR Outstanding Achievement Award for Service to Cancer Science and Medicine during the American Association for Cancer Research Annual Meeting in San Diego.
The presentation will occur during the meeting’s Opening Ceremony on April 7. AACR chose Pfizer and Bourla for their dedication to developing new cancer therapies and their commitment to the AACR.
“Pfizer’s sustained and ongoing contributions to progress against cancer are an inspiration to the entire cancer research community,” Margaret Foti, PhD, MD (hc), CEO of the AACR, said in a press release. “We look forward to celebrating Dr. Bourla and his distinguished colleagues at Pfizer for their stalwart commitment to the cause and for their many remarkable scientific achievements.”
Pfizer announced in December it would donate royalties earned in the U.S. from avelumab (Bavencio) to the AACR, which the organization plans to use to further its research in prevention, treatment and cures for cancer.
Pfizer and the AACR have partnered for several years in meetings and think tanks to improve cancer care.
“Pfizer is committed to the fight against cancer and will continue to collaborate across the health care ecosystem so that we can deliver the next generation of cancer care,” Bourla said in the release. “It is an honor to be recognized by the AACR for the work Pfizer colleagues do every day to bring new innovations for patients everywhere.”
Read more about
Click Here to Manage Email Alerts